News from regado biosciences, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 25, 2014, 06:30 ET

Regado Biosciences Permanently Halts REGULATE-PCI Clinical Trial

 Regado Biosciences, Inc.  today announced the permanent termination of enrollment in its REGULATE-PCI phase 3 trial for its lead program,...

Aug 11, 2014, 16:30 ET

Regado Biosciences Announces Second Quarter 2014 Financial Results and Corporate Highlights

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys™ Kit...

Jul 29, 2014, 16:10 ET

Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys™ Kit...

Jul 09, 2014, 16:05 ET

Regado Biosciences Announces Clinical Hold of REGULATE-PCI Trial Following Voluntary Halt of Trial by Regado

Regado Biosciences, Inc., (NASDAQ: RGDO) today announced that, further to their decision to voluntarily pause enrollment in their REGULATE-PCI...

Jul 02, 2014, 18:13 ET

Regado Announces Initiation Of DSMB Review Of REGULATE-PCI Data

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys™ Kit...

Jun 23, 2014, 07:30 ET

Regado Biosciences' REG2 Demonstrates Dose and Concentration-Dependent Suppression of Thrombin Generation

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the discovery and development of actively controllable aptamer...

Jun 18, 2014, 07:30 ET

Regado Biosciences Appoints Pharmaceutical Business Leader Drew Fromkin to Board of Directors

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys™ Kit (also...

May 29, 2014, 07:30 ET

Regado Biosciences to Present at the Jefferies 2014 Global Healthcare Conference

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys™ Kit...

May 19, 2014, 07:30 ET

Regado Biosciences Appoints Nicholas Pelliccione, Ph.D., Senior Vice President of Regulatory Affairs and Quality Assurance and Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys™ Kit...

May 14, 2014, 07:30 ET

Regado Biosciences Announces First Quarter 2014 Financial Results and Corporate Highlights

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of the...

May 09, 2014, 07:30 ET

Regado Biosciences Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively...

May 07, 2014, 07:30 ET

Regado Biosciences to Provide First Quarter 2014 Financial Results and Corporate Highlights

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class,...

May 01, 2014, 07:30 ET

Regado Biosciences Appoints R. Don Elsey Chief Financial Officer

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively...

Apr 16, 2014, 09:35 ET

Regado Biosciences Announces Closing of Public Offering of Common Stock

 Regado Biosciences, Inc. (Nasdaq: RGDO), today announced the closing of its previously announced underwritten public offering. The gross...

Apr 11, 2014, 07:30 ET

Regado Biosciences Announces Pricing of Public Offering of Common Stock

 Regado Biosciences, Inc. (Nasdaq: RGDO), today announced the pricing of its previously announced underwritten public offering of 10,000,000...

Apr 02, 2014, 21:20 ET

Regado Achieves 1,000-Patient Milestone in Phase 3 Trial of REG1

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company leading the development of actively controllable therapeutics for acute care...

Mar 20, 2014, 07:30 ET

Regado Biosciences to Present at the 21st Annual Future Leaders in the Biotech Industry Conference

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of its...

Mar 12, 2014, 17:35 ET

Regado Biosciences Announces Year-End 2013 Financial Results and Corporate Highlights

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of its...

Mar 10, 2014, 07:30 ET

FDA Designates Regado's REG1 in PCI as a Fast Track Development Program

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the development of actively controllable therapeutics, today...

Mar 06, 2014, 07:30 ET

Regado Biosciences to Provide Year-End and Fourth Quarter 2013 Financial Results

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class,...